Results 121 to 130 of about 30,760,747 (299)

The Changing Landscape of Heart Failure Drug Clinical Trials in China, 2013–2023

Drug Design, Development and Therapy
Wenjie Zhang,1,2,* Yinming Zhang,3,* Jiawei Tang,4,* Xuejiao Wang,1 Chao Meng,1,2 Ji Wu,1 Jun Li1 1Department of Cardiology, Guang’Anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, People’s Republic of China ...
Zhang W, Zhang Y, Tang J, Wang X, Meng C, Wu J, Li J   +6 more
doaj  

RESEARCH ETHICS COMMITTEES (RECs) AND MONITORING OF BIOMEDICAL RESEARCH IN PAKISTAN

Khyber Medical University Journal, 2013
Global health is facing enormous challenges and medical research is the only way to cope with these challenges. Worldwide, extensive clinical research is being conducted in all fields of medicineto resolve the health related issues through best available
Akhtar Sherin
doaj  

Sertraline Treatment Can Mimic Niemann‐Pick Type C Biomarker Profile: A Diagnostic Pitfall

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Oxysterols (cholestane‐3β,5α,6β‐triol and 7‐ketocholesterol) and N‐palmitoyl‐O‐phosphocholineserine (PPCS) are sensitive biomarkers for Niemann‐Pick disease type C (NPC) screening. However, false‐positive results occur, with a biomarker profile suggestive of NPC despite the absence of pathogenic variants in genes involved in NPC or ...
Maria Makrygianni, Cecile Pagan, Antony Citterio‐Quentin, Isabelle Rouvet, Giulia Dingeo, Cyril Hanin, Claudine Laurent‐Levinson, Samia Pichard, Bénédicte Héron, Clément Gourguechon, Daniele Mandia, Jerome Guitton, Carole Lacout, Nicolas Schleinitz, Florient Potier, Olivier Flabeau, Elsa Besse‐Pinot, Foudil Lamari, Magali Pettazzoni, Yann Nadjar   +19 more
wiley   +1 more source

Research Report 2008–2009 [PDF]

, 2010
The NHMRC Clinical Trials Centre at the University of Sydney runs large multicentre investigator-initiated clinical trials, takes part in trials of national and international collaborative trial groups and contributes expertise to trials run by others ...
NHMRC Clinical Trials Centre
core  

Data monitoring and interim analyses in the pharmaceutical industry: ethical and logistical considerations.

, 1993
The characteristics of data monitoring and the need for the use of data monitoring committees in clinical trials sponsored by the pharmaceutical industry differ from those of trials sponsored by government.
Enas, GG, Rockhold, FW, Frank W. Rockhold, Gregory G. Enas   +3 more
core   +1 more source

Undertaking Studies Within A Trial to evaluate recruitment and retention strategies for randomised controlled trials: lessons learnt from the PROMETHEUS research programme

Health Technology Assessment
Background Randomised controlled trials (‘trials’) are susceptible to poor participant recruitment and retention. Studies Within A Trial are the strongest methods for testing the effectiveness of strategies to improve recruitment and retention.
Adwoa Parker, Catherine Arundel, Laura Clark, Elizabeth Coleman, Laura Doherty, Catherine Elizabeth Hewitt, David Beard, Peter Bower, Cindy Cooper, Lucy Culliford, Declan Devane, Richard Emsley, Sandra Eldridge, Sandra Galvin, Katie Gillies, Alan Montgomery, Christopher J Sutton, Shaun Treweek, David J Torgerson   +18 more
doaj   +1 more source

THE ETHICAL STARTUP?

Voices in Bioethics
Photo ID 345549 © Jonathan Mulkey | Dreamstime.com Abstract Emerging DNA marketplace startups aim to empower individuals with greater control and potential profit-sharing over their genetic data, but they face ethical tensions in navigating ...
Alexis Walker
doaj   +1 more source

Safety and data monitoring committees for clinical trials [PDF]

Clinical Cardiology, 1995
openaire   +2 more sources

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin, Binbin Xue, Dewei Xie, Jia Li, Juyuan Pan, Lanbing Zhu, Qiaowen Tong, Jing Lin, Ruofan Zhu, Xu Zhang, Junhui Xia, Xiang Li   +11 more
wiley   +1 more source

Long‐Term Efficacy of Immunotherapy in Autoimmune Autonomic Ganglionopathy—A 10‐Year Follow Up Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Autoimmune autonomic ganglionopathy (AAG) is a rare but potentially treatable cause of severe autonomic failure. Evidence guiding long‐term immunotherapy, treatment sequencing, and residual autonomic impairment is limited. We evaluated long‐term treatment response, residual autonomic dysfunction, and relapse patterns in patients with
Giacomo Chiaro, Shiwen Koay, Gordon T. Ingle, Patricia McNamara, Laura Watson, Fion Bremner, Valeria Iodice   +6 more
wiley   +1 more source